This study was funded by Daiichi Sankyo. T Mok has received grant/research support paid to institution from AstraZeneca, Bristol Myers Squibb, G1 Therapeutics, MSD, Merck Serono, Novartis, Pfizer, Roche, SFJ Pharmaceutical, Takeda, XCovery; speaker's fees from ACEA Therapeutics, Alpha Biopharma, Amgen, Amoy Diagnostics, AstraZeneca (before 1 January 2019), BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Daz Group, Fishawack Facilitate, InMed Medical Communication, Janssen Pharmaceutica NV, Jiahui Holdings, LiangYiHui Healthcare, Lilly, Lucence Health, MD Health Brazil, Medscape, Merck Pharmaceuticals HK, MSD, MiRXES, Novartis, OrigiMed, P. Permanyer SL, PeerVoice, Physicians' Education Resource (PER), Pfizer, prIME Oncology, Research to Practice, Roche, Sanofi, Shanghai BeBirds Translation & Consulting, Shanghai Promedican Pharmaceuticals, Taiho Pharmaceutical, Takeda, Touch Independent Medical Education; honoraria for consultation services from AbbVie, ACEA Therapeutics, Adagene, Alpha Biopharma, Amgen, Amoy Diagnostics, AstraZeneca (before 1 January 2019), AVEO Pharmaceuticals, Bayer Healthcare Pharmaceuticals, BeiGene, BerGenBio, Berry Oncology, Boehringer Ingelheim, Blueprint Medicines, Bristol Myers Squibb, Bowtie Life Insurance Company, Bridge Biotherapeutics, Covidien LP, C4 Therapeutics, Cirina, CStone Pharmaceuticals, Curio Science, D3 Bio, Da Volterra, Daiichi Sankyo, Eisai, Elevation Oncology, F. Hoffmann-La Roche, Genentech, GLG's Healthcare, Fishawack Facilitate, G1 Therapeutics, geneDecode, Gilead Sciences, Gritstone Oncology, Guardant Health, Hengrui, HutchMed, lgnyta, lllumina, Incyte Corporation, Inivata, IQVIA, Janssen, Lakeshore Biotech, Lilly, Lunit USA, Loxo Oncology, Lucence Health, Medscape/WebMD, Medtronic, Merck Serono, MSD, Mirati Therapeutics, MiRXES, MOREHealth, Novartis, Novocure, Omega Therapeutics, OrigiMed, OSE Immunotherapeutics, PeerVoice, Pfizer, prIME Oncology, Prenetics, Puma Biotechnology, Qiming Venture Partners, Regeneron, Roche, Sanofi, SFJ Pharmaceutical, Simcere, Summit Therapeutics, Synergy Research, Takeda Pharmaceuticals HK, Tigermed, Vertex Pharmaceuticals, Virtus Medical, Xencor, Yuhan; stock shareholder in AstraZeneca, Aurora Tele-Oncology, Biolidics Ltd, HutchMed, Prenetics; stock options in Bowtie Life Insurance Company, D3 Bio, Lakeshore Biotech, Loxo Oncology, Lunit USA, Virtus Medical; participation on advisory board for AbbVie, ACEA Therapeutics, Amgen, AstraZeneca, BerGenBio, Berry Oncology, Blueprint Medicines, Boehringer lngelheim, Bowtie Life Insurance Company, Bristol Myers Squibb, C4 Therapeutics, Covidien LP, CStone Pharmaceuticals, Curio Science, D3 Bio, Daiichi Sankyo, Eisai, Fishawack Facilitate, G1 Therapeutics, Gilead Sciences, Gritstone Oncology, Guardant Health, geneDecode (uncompensated), Hengrui, HutchMed, Ignyta, Incyte Corporation, Imagene AI, Inivata, IQVIA, Janssen, Lakeshore Biotech, Lilly, Loxo Oncology, Lunit, Merck Serano, MSD, Mirati Therapeutics, MiRXES, Novartis, OrigiMed, Pfizer, Puma Biotechnology, Roche/Genentech, Regeneron, Sanofi, SFJ Pharmaceutical, Simcere, Simcere Zaiming, Takeda, Vertex Pharmaceuticals, Virtus Medical, Yuhan; board of directors/leadership roles (remunerated) for AstraZeneca, HutchMed, Aurora Tele-Oncology; board of directors/leadership roles (non-remunerated) for American Society of Clinical Oncology (ASCO) (2018–2022), Asian Thoracic Oncology Research Group (ATORG) (2016–Present), Chinese Lung Cancer Research Foundation Limited (CLCRF) (2005–2012), Chinese Society of Clinical Oncology (CSCO) (2009–2020), Hong Kong Cancer Fund (HKCF) (2011–Present), Hong Kong Cancer Therapy Society (HKCTS) (2004–Present), International Association for the Study of Lung Cancer (IASLC) (2007–2019), St. Stephen's College & Preparatory School (2017–Present), Hong Kong Academy of Sciences (ASHK) (2022–Present). PA Jänne has received consulting fees from Pfizer, Boehringer Ingelheim, AstraZeneca, Merrimack, Chugai Pharmaceuticals, Roche/Genentech, LOXO, Mirati Therapeutics, Araxes Pharma, Ignyta, Lilly, Takeda, Novartis, Biocartis, Voronoi Health Analytics, SFJ Pharmaceuticals Group, Sanofi, Biocartis, Daiichi Sankyo, Silicon Therapeutics, Nuvalent, Eisai, Bayer, Syndax, AbbVie, Allorion Therapeutics, Accutar Biotech, Transcenta, Monte Rosa Therapeutics, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotechnology, and Duality Therapeutics; received postmarketing royalties for a DFCI owned patent on EGFR mutations licensed to Labcorp; stock ownership in Gatekeeper Pharmaceuticals; received research funding from AstraZeneca, Astellas Pharma, Daiichi Sankyo, Lilly, Boehringer Ingelheim, Puma Biotechnology, Takeda, and Revolution Medicines. M Nishio has received payment/honoraria for lectures from Ono Pharmaceuticals, Chugai Pharmaceutical, Taiho Pharmaceutical, Bristol Myers Squibb, Daiichi Sankyo, Lilly, AstraZeneca, MSD, AbbVie, Takeda, Pfizer, Boehringer Ingelheim, Novartis, Nippon Kayaku, Merck, and Janssen. S Novello has received invited speaker fees from AstraZeneca, MSD, Eli Lilly, Novartis, BeiGene, and Amgen; served on advisory board for Boehringer Ingelheim, BMS, Pfizer, Takeda, Roche, Sanofi, and Amgen; institutional fees coordinating principal investigator for investigator-initiated trial from MSD and Boehringer Ingelheim; nonfinancial leadership role as president of Women Against Lung Cancer in Europe. M Reck has received invited speaker fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Merck, Novartis, Regenero, Roche, and Sanofi; served on advisory board for Amgen, AstraZeneca, BMS, BioNTech, Boehringer Ingelheim, Daiichi Sankyo, Gilead, MSD, Mirati, Pfizer, Regeneron, Sanofi, and Roche; membership on board of directors or advisory committee for Daiichi Sankyo. Conor Steuer has received honoraria from AbbVie, BerGenBio, Armo, Eli Lilly, Merck, Daiichi Sankyo, G1, Caris, Amhearst, Sanofi, and Regeneron; payment for advisory board and steering committee from Daiichi Sankyo; consulting fees from AbbVie, BerGenBio, ARMO BioSciences, Lilly, Mirati Therapeutics, Sanofi/Regeneron, and Caris Life Sciences; received honoraria from Merck; received research funding from Vaccinex, Seagen, Daiichi Sankyo, and Infinity Pharmaceuticals. Y-L Wu has received consulting fees from AstraZeneca, Roche, Boehringer Ingelheim, and Takeda; received honoraria from AstraZeneca, Lilly, Roche, Pfizer, Boehringer Ingelheim, MSD Oncology, Bristol Myers Squibb, Hengrui Pharmaceutical, and BeiGene Beijing; received research funding from Boehringer Ingelheim, Roche, Pfizer, and Bristol Myers Squibb. R Fougeray, P-D Fan, J Meng, DW Sternberg, and S Esker are employees of and have stock ownership in Daiichi Sankyo. HA Yu has received consulting fees from AstraZeneca, Daiichi Sankyo, Blueprint Medicines, Janssen, C4 Therapeutics, Cullinan Oncology, and Black Diamond Therapeutics; received travel, accommodation, and/or expenses from Lilly; other relationship with Astellas Pharma; received research funding from AstraZeneca, Astellas Pharma, Lilly, Novartis, Pfizer, Daiichi Sankyo, Cullinan Oncology, Janssen Oncology, Erasca, and Blueprint Medicines. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.